未登录

F

Faisal M. Khan

AstraZeneca

H指数:23

被引数:2,158

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiclass Synthetic Accessibility Prediction

JOURNAL OF CHEMICAL INFORMATION AND MODELING

IF5.3

2025-01-170

PRE

Reconstitution of T cells at three months after stem cell transplant influences fl uences the discovery of predictive markers of relapse

HUMAN IMMUNOLOGY

IF2.2

2024-09-010

PRE

Early detection of acute graft versus host disease by assessment of the immunity related transcriptome

HUMAN IMMUNOLOGY

IF2.2

2024-09-010

PRE

Significance of Digital Health Technologies (DHTs) to manage communicable and non-communicable diseases in Low and Middle-Income Countries (LMICs)

数字卫生技术 (DHTs) 在低收入和中等收入国家 (LMICs) 管理传染性和非传染性疾病的意义

health technology assessment

IF2.8

2023-11-162

PRE

Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder

优先或治疗性给予移植后淋巴增生性疾病后的利妥昔单抗毒性

TRANSPLANTATION AND CELLULAR THERAPY

IF4.4

2023-01-019

OAAI

Accurate Step Count with Generalized and Personalized Deep Learning on Accelerometer Data

IF3.5

2022-05-2413

OAAI

OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials

JCO CLINICAL CANCER INFORMATICS

IF2.8

2022-05-013

OAAI

Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis

FRONTIERS IN ONCOLOGY

IF3.3

2021-07-2619

OAAI

CORRELATION BETWEEN EARLY ENDPOINTS AND OVERALL SURVIVAL IN NON-SMALL-CELL LUNG CANCER: A TRIAL-LEVEL META-ANALYSIS

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2020-11-090

OAAI

The value of onasemnogene abeparvovec (AVXS-101) gene-replacement therapy for spinal muscular atrophy type 1

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2019-10-011

PREAI

Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test.

CANCER RESEARCH

IF16.6

2018-08-140

PRE

Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test

PROSTATE CANCER AND PROSTATIC DISEASES

IF5.8

2018-08-0720

PREAI

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

CLINICAL CANCER RESEARCH

IF10.2

2017-03-1473

OAAI

Chen, Ying; Camacho, Sandra Catalina; Silvers, Thomas R.; Razak, Albiruni R. A.; Gabrail, Nashat Y.; Gerecitano, John F.; Kalir, Eva; Pereira, Elena; Evans, Brad R.; Ramus, Susan J.; Huang, Fei; Priedigkeit, Nolan; Rodriguez, Estefania; Donovan, Michael; Khan, Faisal; Kalir, Tamara; Sebra, Robert; Uzilov, Andrew; Chen, Rong; Sinha, Rileen; Halpert, Richard; Billaud, Jean-Noel; Shacham, Sharon; McCauley, Dilara; Landesman, Yosef; Rashal, Tami; Kauffman, Michael; Mirza, Mansoor R.; Mau-Sorensen, Morten; Dottino, Peter; Martignetti, John A.

Multi-phase classification by a least-squares support vector machine approach in tomography images of geological samples

IF2.7

2016-03-3013

OAAI

Processing of rock core microtomography images: Using seven different machine learning algorithms

COMPUTERS & GEOSCIENCES

IF4.4

2016-01-0183

PREAI

Simultaneous segmentation and beam-hardening correction in computed microtomography of rock cores

COMPUTERS & GEOSCIENCES

IF4.4

2013-07-0127

PREAI

Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery

BJU INTERNATIONAL

IF4.4

2011-07-194

OAAI

A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer

BJU INTERNATIONAL

IF4.4

2011-07-064

PREAI

COST-MINIMIZATION ANALYSIS OF BIOPSY-BASED RISK STRATIFICATION TOOLS IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER PATIENTS BASED ON RESULTS FROM PHYSICIAN CASE STUDIES

VALUE IN HEALTH

IF6

2011-05-010

OAAI

Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men

PROSTATE CANCER AND PROSTATIC DISEASES

IF5.8

2011-04-2654

PREAI